Business Context and Reporting Period
This Form 8-K is a current report filed by LIFECORE BIOMEDICAL, INC. on March 5, 2026. The filing addresses corporate governance matters related to a change in the Company's fiscal year and the scheduling of its 2026 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and focuses solely on shareholder meeting logistics.
Material Changes
- Fiscal Year Change: On August 1, 2025, the Board approved changing the fiscal year from ending on the last Sunday of May to a calendar year ending on December 31, effective for the period beginning May 26, 2025.
- Annual Meeting Date Shift: The 2026 Annual Meeting is scheduled for June 4, 2026. This represents a shift of more than 30 days from the anniversary of the 2025 Annual Meeting (held October 29, 2025) due to the fiscal year alignment.
Guidance, Outlook, and Shareholder Procedures
Management intends to align Annual Meetings and Definitive Proxy Statements with the timing of calendar year reporting companies. Due to the date change, strict deadlines apply for shareholder proposals and director nominations:
- Submission Deadline: Qualified shareholder proposals or nominations must be received by March 16, 2026.
- Compliance Requirements: Submissions must comply with Rule 14a-8, Rule 14a-18, Rule 14a-19(b) of the Exchange Act, the Company's Bylaws, and Delaware state law.
- Submission Address: Notices must be sent to the Company Secretary at 3515 Lyman Blvd., Chaska, MN 55318.
Key Facts for Investor Verification
- Verify the new fiscal year end date of December 31 for future financial reporting periods.
- Confirm the 2026 Annual Meeting date of June 4, 2026, for voting and attendance planning.
- Note the March 16, 2026 deadline for submitting shareholder proposals or director nominations.
- Review the Company's Bylaws for specific formatting and eligibility requirements for nominations.